arvinas logo.jpg
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
01 mars 2021 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...
arvinas logo.jpg
Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day
08 févr. 2021 16h30 HE | Arvinas Inc.
NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas logo.jpg
Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
28 déc. 2020 16h30 HE | Arvinas Inc.
NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...
arvinas logo.jpg
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
15 déc. 2020 20h35 HE | Arvinas Inc.
NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...
arvinas logo.jpg
Arvinas, Inc. Announces Proposed Offering of Common Stock
14 déc. 2020 16h06 HE | Arvinas Inc.
NEW HAVEN, Conn., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...
arvinas logo.jpg
Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110
14 déc. 2020 07h00 HE | Arvinas Inc.
– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated...
arvinas logo.jpg
Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs
11 déc. 2020 16h15 HE | Arvinas Inc.
– Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET – NEW HAVEN, Conn., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology...
arvinas logo.jpg
Arvinas to Participate in Upcoming Virtual Investor Conferences
25 nov. 2020 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas logo.jpg
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
05 nov. 2020 07h00 HE | Arvinas Inc.
– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial – – Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues; program updates planned for December 2020 –...
arvinas logo.jpg
Arvinas Announces Pipeline Programs Targeting Validated and Classically “Undruggable” Disease-Causing Proteins
14 oct. 2020 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...